What changed from existing technology?
This study looks at how research on making artificial corneas is moving towards real-world use, checking things like new discoveries, patents, companies working on it, and how cost-effective it might be.
This is the first study to integrate multiple translational factors including scientific development, intellectual property, commercialization, health economics, and clinician perspectives in corneal endothelial tissue engineering.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
lational framework that combined bibliometric mapping, patent activity, identification of companies and technology development status, an exploratory scenar
Abstract ↗OpenAlex author affiliations: Biodesigns (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This review provides a comprehensive framework for evaluating the translational potential of corneal endothelial tissue engineering technologies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchTranslation Landscape of Corneal Endothelial Tissue Engineering: A Scoping ReviewF1000Research · Published 2026-09-18 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.